Berkshire Hathaway reveals $4.3 billion stake in Alphabet, cuts Apple
Investing.com - RBC Capital has raised its price target on Cytokinetics (NASDAQ:CYTK) to $87.00 from $82.00 while maintaining an Outperform rating on the stock. The company, currently trading at $62.20, has seen a remarkable 96.25% price return over the past six months and is trading near its 52-week high of $64.13.
The adjustment comes as RBC updates its modeling assumptions for Cytokinetics’ anticipated 2026 launch of aficamten following the December 2025 PDUFA date.
RBC’s analysis focuses on projected operating expenses and revenue forecasts that reflect potential early U.S. launch dynamics in 2026, using historical competitor data as benchmarks.
The investment firm believes aficamten is likely to receive a differentiated REMS (Risk Evaluation and Mitigation Strategy), which could drive patient and physician preference over competing treatments.
RBC projects aficamten will outperform Bristol Myers Squibb’s Camzyos and achieve more than $2.6 billion in U.S. sales for obstructive hypertrophic cardiomyopathy (oHCM) by 2034.
In other recent news, Cytokinetics Inc. reported its third-quarter 2025 earnings, highlighting a significant revenue shortfall. The company disclosed an actual earnings per share (EPS) of -$2.55, which was a considerable miss compared to the forecasted -$1.57. Revenue figures were also notably lower than expected, with the company reporting $1.93 million against a projected $6.05 million, resulting in a 68.1% revenue miss. Despite these financial results, the stock price showed only slight fluctuations in the trading sessions following the earnings announcement. These developments have captured the attention of investors and analysts alike, focusing on the company’s financial health and future prospects. Analyst firms may provide further insights or adjustments to their forecasts based on this earnings report. Investors are likely to keep a close watch on any strategic moves or announcements from Cytokinetics in response to these results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.